Irinotecan pharmacokinetics-pharmacodynamics: The clinical relevance of prolonged exposure to SN-38

British Journal of Cancer

Volumn 87, Issue 2, 2002, Pages 144-150

  Mathijssen, R H J ^a   Verweij, J ^a   Loos, W J ^a   De Bruijn, P ^a   Nooter, K ^a   Sparreboom, A ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Irinotecan; Limited sampling; Pharmacodynamics; Pharmacokinetics; SN 38

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; DRUG METABOLITE; IRINOTECAN;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CANCER; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOTOXICITY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DISPOSITION; DRUG HALF LIFE; HUMAN; NEUTROPHIL; PHARMACODYNAMICS; PRIORITY JOURNAL;

ADULT; AGED; ANTINEOPLASTIC AGENTS, PHYTOGENIC; AREA UNDER CURVE; CAMPTOTHECIN; COLONIC NEOPLASMS; COLORECTAL NEOPLASMS; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEUTROPENIA; OVARIAN NEOPLASMS; PRODRUGS; RANDOM ALLOCATION; TUMOR CELLS, CULTURED; UTERINE CERVICAL NEOPLASMS;

EID: 0037100863     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjc.6600447     Document Type: Article

References (29)

1. Biliary excretion mechanism of CPT-11 and its metabolites in humans: Involvement of primary active transporters
2. Possible involvement of P-glycoprotein in biliary excretion of CPT-11 in rats
3. Determination of irinotecan (CPT-11) and its active metabolite SN-38 in human plasma by reversed-phase high-performance liquid chromatography with fluorescence detection
4. Femtomole quantitation of 7-ethyl-10-hydroxycamptothecine (SN-38) in plasma samples by reversed-phase high-performance liquid chromatography
5. Nonlinear pharmacokinetics and metabolism of paclitaxel and its pharmacokinetic/pharmacodynamic relationships in humans
6. Factors affecting epirubicin pharmacokinetics and toxicity: Evidence against using body-surface area for dose calculation
7. Metabolism of irinotecan (CPT-11) by human hepatic microsomes: Participation of cytochrome P-450 3A and drug interactions
8. Modification of the hydroxy lactone ring of camptothecin: Inhibition of mammalian topoisomerase I and biological activity
9. Understanding the dose-effect relationship: Clinical application of pharmacokinetic-pharmacodynamic models
10. Characterization of CPT-11 hydrolysis by human liver carboxylesterase isoforms hCE-1 and h-CE-2
11. Genetic predisposition to the metabolism of irinotecan (CPT-11). Role of uridine diphosphate glucuronosyltransferase isoform 1A1 in the glucuronidation of its active metabolite (SN-38) in human liver microsomes
12. A general model for time-dissociated pharmacokinetic-pharmacodynamic relationships exemplified by paclitaxel myelosuppression
13. Factors involved in prolongation of the terminal disposition phase of SN-38: Clinical and experimental studies
14. Modulation of Mnotecaninduced diarrhea by co-treatment with neomycin in patients with metaboom static colorectal cancer
15. Modulation of camptothecin analogues in the treatment of cancer, a review
16. Modulation of irinotecan metabolism by ketoconazole
17. Sparse-data set analysis for irinotecan and SN-38 pharmacokinetics in cancer patients cotreated with cisplatin
18. Clinical pharmacokinetics and metabolism of irinotecan (CPT-11)
19. Impact of body-size measures on irinotecan clearance: Alternative dosing recommendations
20. Differential distribution and red-cell partitioning of irinotecan (CPT-11) and SN-38 in cancer patients
21. Indirect-response model for the time course of leukopenia with anticancer drugs
22. Pharmacodynamic modeling of the entire time course of leukopenia after a 3-hour infusion of paclitaxel
23. Clinical pharmacokinetics and pharmacodynamics of paclitaxel: A 3-hour infusion versus a 24-hour infusion
24. Metabolism of irinotecan (CPT-11) by CYP3A4 and CYP3A5 in humans
25. Pharmacological correlation between total drug concentration and lactones of CPT-11 and SN-38 in patients treated with CPT-11
26. Pharmacokinetics, metabolism, and excretion of irinotecan (CPT-11) following I.V. infusion of [(14)C]CPT-11 in cancer patients
27. Irinotecan (CPT-11) metabolism and disposition in cancer patients
28. Irinotecan in the treatment of colorectal cancer: Clinical overview